lapatinib has been researched along with 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide) | Trials (5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide) | Recent Studies (post-2010) (5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 21 | 0 | 5 |
| Protein | Taxonomy | lapatinib (IC50) | 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.0285 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.005 | |
| Integrase | Human immunodeficiency virus 1 | 0.5167 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debnath, B; Ding, J; Kazemi, R; Long, YQ; Neamati, N; Odde, S; Sanchez, TW; Wang, Y; Xie, H; Xu, S; Xu, ZL; Yang, LM; Zeng, LF; Zheng, YT | 1 |
1 other study(ies) available for lapatinib and 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide
| Article | Year |
|---|---|
Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Topics: Antineoplastic Agents; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Integration | 2012 |